Zydus Cadila completes Phase 3 Trial of Saroglitazar Magnesium

02 Aug 2019

Zydus Cadila has completed Phase 3 Clinical Trial in India of Saroglitazar Magnesium for treating Type 2 Diabetes. The trial was a multi-centric, randomized, double blind study to evaluate the safety and efficacy of 2mg and 4mg of Saroglitazar compared to Pioglitazone 45mg in patients with Type 2 Diabetes Mellitus. The Phase 3 trial enrolled 1140 subjects and studied the patients over a period of 56 weeks.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Related Cadila Healthcare Ltd. Links:

Cadila Healthcare Share Price

271.95 2.85 (1.06%) Jan 24, 18:01
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 447.70
Lupin 740.10
Dr. Reddys Lab 3028.05
Piramal Enterprises 1676.55
Cadila Healthcare 271.95
View more..
Sensex vs Cadila Healthcare
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback

8055769463

8055769463